ReviewAIDS (London, England)2018
p24 revisited: a landscape review of antigen detection for early HIV diagnosis.
Review in AIDS (London, England), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 71 citations in OpenAlex.
- Analytical and Clinical Performance of VIDASDiagnostics (Basel, Switzerland) · 2026Article
- A luciferase immunoprecipitation system-based ultra-sensitive assay for HIV-1 p24 IgG in serum.Analytical and bioanalytical chemistry · 2026Article
- Laboratory test availability and user fees in routine HIV care: a global analysis in 42 countries.Health affairs scholar · 2026Article
- Article
- Different approaches to HIV confirmation: a survey of three Italian regions.Frontiers in cellular and infection microbiology · 2026Article
- Ultra-low level HIV p24 drives immune activation in antiretroviral therapy-treated people living with HIV.Communications medicine · 2025Article
- HIV Virion Capturing Liposomes for Therapeutic Vaccination.bioRxiv : the preprint server for biology · 2025Article
- A luminescence-based point-of-care HIV viral load test for antiretroviral therapy monitoring.Lab on a chip · 2025Article
- Antibody-Initiated Loop-Mediated Isothermal Nucleic Acid Amplification (ai-LAMP) as a New Biosensor for Antigen Detection.bioRxiv : the preprint server for biology · 2025Article
- Recent HIV Infections in Italy: Data from the HIV National Surveillance System, 2012-2023.Pathogens (Basel, Switzerland) · 2025Article
- Recombinant CA Protein-Based ELISA for Serological Detection of Small Ruminant Lentiviruses Antibodies.Transboundary and emerging diseases · 2025Article
- Development and Application of an Antigen Capture ELISA for the Detection of Enzootic Nasal Tumor Virus-2.Transboundary and emerging diseases · 2025Article
- Stakeholder considerations on acceptability and implementation of a novel rapid test for acute HIV infection: A qualitative study in Indiana.PLOS global public health · 2025Article
- Evaluation of a new human immunodeficiency virus antigen and antibody test using light-initiated chemiluminescent assay.Frontiers in cellular and infection microbiology · 2025Article
- Isolation of Peptide Ligands for the HIV Capsid Protein p24 by Phage-Display.International journal of peptide research and therapeutics · 2025Article
- Development and characterization of high-affinity aptamers for HIV protease detection.Heliyon · 2024Article
- Development and evaluation of a high-sensitivity RT-PCR lateral flow assay for early detection of HIV-1 infection.Heliyon · 2024Article
- Biomolecular Interaction Analysis Quantification with a Low-Volume Microfluidic Chip and Particle Diffusometry.Analytical chemistry · 2024Article
- Combining Bioorthogonal Chemistry with Fluorescent Silica Nanoparticles for the Ultrasensitive Detection of the HIV-1 p24 Antigen.ACS omega · 2024Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 2 countries.
Funding
Abstract
: Despite major advances in HIV testing, early detection of infection at the point of care (PoC) remains a key challenge. Although rapid antibody PoC and laboratory-based nucleic acid amplification tests dominate the diagnostics market, the viral capsid protein p24 is recognized as an alternative early virological biomarker of infection. However, the detection of ultra-low levels of p24 at the PoC has proven challenging. Here we review the landscape of p24 diagnostics to identify knowledge gaps and barriers and help shape future research agendas. Five hundred and seventy-four research articles to May 2018 that propose or evaluate diagnostic assays for p24 were identified and reviewed. We give a brief history of diagnostic development, and the utility of p24 as a biomarker in different populations such as infants, the newly infected, those on preexposure prophylaxis and self-testers. We review the performance of commercial p24 assays and consider elements such as immune complex disruption, resource-poor settings, prevalence, and assay antibodies. Emerging and ultrasensitive assays are reviewed and show a number of promising approaches but further translation has been limited. We summarize studies on the health economic benefits of using antigen testing. Finally, we speculate on the future uses of high-performance p24 assays, particularly, if available in self-test format.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.